6-Thioguanine: A new old drug to procure remission in inflammatory bowel disease

Internal Medicine Journal

Volumn 33, Issue 1-2, 2003, Pages 44-46

  Cheung, Ting Kin ^a,b   Florin, T H J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b MATER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; 6 METHYLTHIOINOSINE; AZATHIOPRINE; BUDESONIDE; DRUG METABOLITE; GLUCOCORTICOID; MERCAPTOPURINE; NEW DRUG; PREDNISOLONE; PRODRUG; TIOGUANINE; TRIACYLGLYCEROL LIPASE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ALLERGIC REACTION; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BONE MARROW DEPRESSION; CLINICAL ARTICLE; CROHN DISEASE; DIARRHEA; DISEASE ACTIVITY; DOSE RESPONSE; DRUG METABOLISM; DRUG WITHDRAWAL; ENTERITIS; FEMALE; FEVER; GASTROINTESTINAL DISEASE; HEADACHE; HEPATITIS; HUMAN; IMMUNOMODULATION; LEUKOPENIA; LIVER DYSFUNCTION; LIVER TOXICITY; MALE; MYALGIA; NAUSEA; PANCREATITIS; PRIORITY JOURNAL; REMISSION; SIDE EFFECT; TRIACYLGLYCEROL LIPASE BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CROHN DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; REMISSION INDUCTION; THIOGUANINE; TREATMENT OUTCOME;

EID: 0037285921     PISSN: 14440903     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1445-5994.2003.00321.x     Document Type: Article

References (8)

1. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease: a meta-analysis. Ann Intern Med 1995; 123: 132-42.
2. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989; 111: 641-9.
3. Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Theoret Y et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705-13.
4. Dubinsky MC, Hassard PV, Seidman EG, Kam LY, Abreu MT, Targan SR et al. An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. Inflamm Bowel Dis 2001; 7: 181-9.
5. Baert F, Rutgeerts P. 6-Thioguanine: a naked bullet? (Or how pharmacogenomics can make old drugs brand new). Inflamm Bowel Dis 2001; 7: 190-1.
6. Kirschner BS. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998; 115: 813-21.
7. Lancaster DL, Lennard L, Rowland K, Vora AJ, Lilleyman JS. Thioguanine versus mercaptopurine for therapy of childhood lymphoblastic leukaemia: a comparison of haematological toxicity and drug metabolite concentrations. Br J Haematol 1998; 102: 439-43.
8. Mortimore M, Gibson PR, Selby WS, Radford-Smith GL, Florin THJ and the Inflixmab User Group. The early Australian experience with infliximab, a chimeric antibody against TNFa in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy? Intern Med J 2001; 31: 146-50.